Predicted to enable natural killer cell lectin-like receptor binding activity. Predicted to be involved in several processes, including antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent; positive regulation of immune response; and response to retinoic acid. Predicted to be active in external side of plasma membrane and extracellular space. Orthologous to human MICA (MHC class I polypeptide-related sequence A) and MICB (MHC class I polypeptide-related sequence B); INTERACTS WITH acrylamide; bisphenol A; glycidol.
MHC class I-like located near the leukocyte receptor complex 2; MHC class I-like located near the LRC, 2; MHC class I-like protein MILL2; MHC I like leukocyte 2; Mill2; Mill2 gene for MHC class I-like located near the LRC, 2, exon 3, partial cds, strain:LEW.1lm1
[Decitabine results in decreased methylation of MICB promoter] which results in increased expression of MICB mRNA and Caffeine inhibits the reaction [[Decitabine results in decreased methylation of MICB promoter] which results in increased expression of MICB protein]
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA
[NOG protein co-treated with methylmercuric chloride co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICB mRNA